CAMBRIDGE, Mass., July 11, 2019 /PRNewswire-PRWeb/ -- rHEALTH LLC, and its affiliate DNA Medicine Institute, Inc., today announced that both of its abstracts have been accepted via peer-review from for the 2019 American Association of Clinical Chemistry (AACC) meeting. The titles and details of the abstracts are as follows:
- Point-of-Care FVIII Test Using an Integrated Microfluidic Consumable with a Fluorogenic Assay, (Poster A-293) on August 6, 2019 at 9:30 AM, Session 07 Hematology and Coagulation
- Point-of-Care Microvolume Cytometer Measures Platelet Counts with High Accuracy from Capillary Blood, Invited Oral Presentation on August 6, 2019 from 2:15 – 2:30 PM
"We are pleased with the acceptance of these abstracts and look forward to sharing our results with the lab medicine community. Our work shows that two very different and complex laboratory tests can be implemented at the point-of-care with high performance using the rHEALTH technology," stated Dr. Eugene Chan, President and CEO.
A point-of-care FVIII test would allow hemophilia A patients and providers to prevent breakthrough bleeding and early detection of inhibitors. Similarly, an accessible test for platelets can allow proper management of thrombocytopenia, a significant side effect of certain drugs or immune disorders.
The rHEALTH blood sensor technology is an award-winning and patented point-of-care technology that has successfully received funding from the National Aeronautics and Space Administration, National Institutes of Health, and XPRIZE. It is currently the subject of multiple collaborations with academia and biopharmaceutical companies. The technology is designed to analyze blood from fingerpricks and generate results in less than 30 minutes for use by consumers and medical professionals.
The 2019 AACC Annual Scientific Meeting & Clinical Lab Expo is the 71st annual conference of the lab medicine community and expects to have over 20,000 professionals in attendance. It will showcase cutting-edge science and technology and will be held in Anaheim, California, from August 4-8.
About rHEALTH®
rHEALTH is a company focused on the development and commercialization of its Diagnose Yourself, AnywhereTM technology. rHEALTH's innovations consists of the rHEALTH diagnostic platform, which enables diverse laboratory test classes in a single small volume blood sample intended as a point-of-care solution, the SKYE Sensor, a wireless wearable providing comprehensive real-time vitals monitoring and CHAS, a user-friendly mobile application. For more information, visit http://www.rhealth.com.
About DNA Medicine Institute
DNA Medicine Institute (DMI) is a biomedical incubator focused on advancing patient care, alleviating human suffering, and treating disease through innovation. Its technology is subject of work funded by NASA, National Institutes of Health, and the Bill & Melinda Gates Foundation. DMI leverages substantial expertise in interdisciplinary science and engineering to solve challenging problems. For more information, visit http://www.dnamedinstitute.com.
SOURCE rHEALTH
Share this article